About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees ( Dec 31, 2011) and is represented in more than 100 countries. More information at http://www.healthcare.bayer.com.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of June 30, 2012, QIAGEN employed approximately 4,000 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com/.Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 , as amended , and Section 21E of the U.S. Securities Exchange Act of 1934 , as amended. To the extent that any of the statements contained herein relating to QIAGEN's products , markets , strategy or operating results , including without limitation its expected operating results , are forward-looking , such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include , but are not limited to , risks associated with management of growth and international operations (including the effects of currency fluctuations , regulatory processes and dependence on logistics) , variability of operating results and allocations between customer classes , the commercial development of markets for our products in applied testing , personalized healthcare , clinical research , proteomics , women's health/ HPV testing and nucleic acid -based molecular diagnostics ; changing relationships with customers , suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions , the level and timing of customers' funding , budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products , the consummation of acquisitions , and the integration of acquired technologies and businesses. For further information , please refer to the discussions in reports that QIAGEN has filed with , or furnished to , the U.S. Securities and Exchange Commission (SEC). Contacts: Public Relations: Dr. Thomas Theuringer Director Public Relations +49-2103-29-11826 +1-240-686-7425 Email: firstname.lastname@example.org http://www.twitter.com/qiagen http://www.qiagen.com/about/press Investor Relations: John Gilardi VP Corporate Communications +49-2103-29-11711 +1-240-686-2222 Albert F. Fleury Investor Relations North America +1-240-686-7400 Email: email@example.com http://www.qiagen.com/about/investorrelation SOURCE Qiagen N V